Member Info for EmeraldCarrots

There are no share holders with even more than 3% of GDR, let alone 75%.

I'm happy to wait while one or more Co's build up their 75% holding by buying shares. LOL!

Wonder what the sp would be when they get there.......... 15p?

Bangle, Tangle, oh no it's Angle!

"Liquid Biopsy Detection of Breast Cancer Recurrence Improves Outcomes"

Https://news.weill.cornell.edu/news/2025/06/switch-to-experimental-drug-after-liquid-biopsy-detection-of-breast-cancer-recurrence

Https://news.weill.cornell.edu/news/2025/06/switch-to-experimental-drug-after-liquid-biopsy-detection-of-breast-cancer-recurrence

Https://www.genedrive.com/assays/cyp2c19-product.php

"Regulatory approval UKCA marked"

It says "stay long now". Erm?

https://www.britishbulls.com/SignalPage.aspx?Ticker=GDR.L&lang=en

Now 6.67%

Up 3.33%

JohnL.

Exactly. How much does if costs the NHS when a baby is made deaf, compared to it not being made deaf? Over a lifetime the cost would be incredible. That baby might live another 90 yesrs, or even more.

As you say. It is scandellous this cheap simple test is not available in all neonatal wards in the UK. They need to GET ON WITH IT !

A load of buys don't turn up soon!

https://www.britishbulls.com/SignalPage.aspx?Ticker=GDR.L&lang=en

When they got CE IVD certification. Just visiting each one would take years!

News on which distributors are to be used in the EU on the way, must be.

Exciting times!

A few more orders and the sp will take off IMHO.

Preferably from the EU now the Genedrive® CYP2C19 is CE marked.

15,000 additional hospitals now potential clients. Nealy 500m people in the EU.

Just a tiny % needed and whoosh!!!!!!!!

1.45/1.55p now but still unusual IMHO.

Odd?

Unreported trade methings, a biggy!

Bid 1.4p/ask 1.55p ?

With updates on the two applications. From the half year report dated 27th March 2004:-

Genedrive® CYP2C19.

· 510(k) route identified for regulatory submission for US market entry, with initial pre-submission engagement with Food and Drug Administration (FDA) held and feedback positive and with regulatory approach confirmed as appropriate.

Genedrive® MT-RNR1

· Breakthrough Device Designation received from the FDA. Progressing as planned, with first-engagement with FDA under programme initiated

===================

Illumina Bid?

Hospitals. No wonder the sp is up!

Of course we have the CE-IVD under IVDR as confirmed in the RNS last Friday.

Expect this next, and indeed this week:-

"with nine Group 1 sites live, with ***a further five Group 2 sites phased to go-live from May 2025***.".